Latest News

Bowhead Specialty Holdings (BOW) opened Q1 2026 with total revenue of US$155.7 million and basic EPS of US$0.49, setting a clear marker for how the year is starting. The company reported an increase in total revenue from US$122.7 million in Q1 2025 to US$155.7 million in Q1 2026, while basic EPS over the same quarters rose from US$0.35 to US$0.49, giving investors a direct view of both top line and per share performance. With trailing net profit margin at around 10%, this set of results keeps...

Relay Therapeutics (RLAY) opened 2026 with Q1 revenue of US$3 million, basic EPS of a US$0.41 loss, and a net loss excluding extra items of US$73.3 million, setting a clear snapshot of where the business is starting the year. The company has seen quarterly revenue move between US$0 and US$7.7 million since early 2024, while basic EPS has ranged from a US$0.32 loss to a US$0.46 loss over the same period, giving investors a consistent view of a revenue generating but loss making biotech with...

FormFactor (FORM) has opened 2026 with Q1 revenue of US$226.1 million and basic EPS of US$0.26, alongside trailing 12 month revenue of US$839.8 million and basic EPS of US$0.88 that reflect the latest reported earnings base. The company has seen quarterly revenue move from US$171.4 million in Q1 2025 to US$226.1 million in Q1 2026, with basic EPS shifting from US$0.08 to US$0.26 over the same period, setting up a results season in which investors can weigh that earnings profile against the...

Earnings reset and guidance cut put Clorox’s near term in focus Clorox (CLX) recently reported mixed third quarter results and sharply reduced its full year earnings outlook, a combination that put margin pressures and execution questions front and center for stock investors. See our latest analysis for Clorox. The updated outlook helped drive a 14.19% 30 day share price decline and a 23.47% 90 day share price return, while the 1 year total shareholder return of 31.08% loss underlines that...

If you are wondering whether Pfizer at a last close of US$26.53 still offers solid value, the starting point is understanding what that price really implies about the business. Over the last year the stock returned 24.9%, with a 5.4% gain year to date, a 1.0% rise over the past week, and a 4.7% decline across the last 30 days, which signals that expectations and perceived risk have been shifting recently. Recent headlines have focused on Pfizer's efforts to reshape its portfolio and...

Global Net Lease (GNL) opened 2026 with Q1 revenue of US$109.3 million and basic EPS of a US$0.09 loss per share, keeping investors focused on how the income statement is tracking against past quarters. The company has seen quarterly revenue move from US$137.8 million in Q4 2024 to US$132.4 million in Q1 2025, then to US$124.9 million, US$121.0 million and US$117.0 million through 2025, alongside basic EPS that has ranged between a loss of US$0.46 per share and a profit of US$0.19 per share...

Novo Nordisk (CPSE:NOVO B) opened 2026 with Q1 revenue of DKK 96.8b and basic EPS of DKK 10.93, while the trailing twelve months show revenue of DKK 327.8b and EPS of DKK 27.44. Over the past year, revenue has moved from DKK 290.4b to DKK 327.8b and EPS from DKK 22.67 to DKK 27.44 on a trailing basis. This sets a clear benchmark for how current profitability aligns with investor expectations. With net margin running at 37.2% versus 34.5% a year earlier, the latest results put the focus...

Fabrinet (FN) has just posted Q3 2026 results with revenue of US$1.2 billion, basic EPS of US$3.49 and net income of US$125.2 million, against a backdrop of 29% reported earnings growth over the last year and a trailing 12 month earnings growth rate of 19.2% per year over the past five years. The company has seen revenue move from US$871.8 million in Q3 2025 through US$909.7 million in Q4 2025 and US$978.1 million in Q1 2026 to US$1.2 billion in Q3 2026. Over the same span, basic EPS has gone...

Karnov Group (OM:KAR) opened 2026 with Q1 revenue of SEK628.1 million and basic EPS of SEK0.55, set against trailing 12 month revenue of SEK2,596.5 million and basic EPS of SEK8.87, alongside very large year on year earnings growth and a 36.7% net margin versus 2.1% a year earlier. Over the past year, the company has seen revenue sit within a SEK2.6 billion range on a trailing basis while EPS over individual quarters moved from a loss of SEK0.09 in Q4 2024 to SEK7.81 in Q4 2025 and SEK0.55 in...

Astera Labs (ALAB) has put up another active quarter, with Q1 2026 revenue of US$308.4 million and basic EPS of US$0.47, at a time when trailing 12 month EPS sits at US$1.59 on revenue of about US$1.0 billion and net income of US$267.6 million. This comes alongside very large year on year earnings growth and higher profit margins over the past year. Over the last five reported quarters, revenue has moved from US$159.4 million in Q1 2025 to US$308.4 million in Q1 2026, while quarterly EPS has...

Jacobs Solutions (J) opened Q2 2026 with revenue of about US$3.7b and a basic EPS loss of US$0.32, putting a negative earnings print alongside a higher top line. The company has seen quarterly revenue move from about US$2.9b in Q2 2025 to about US$3.7b in Q2 2026, while basic EPS shifted from US$0.10 in Q2 2025 to a loss of US$0.32 this quarter, setting up a mixed read on growth versus profitability that puts the spotlight firmly on margins and earnings quality. See our full analysis for...

Why Fairfax’s latest quarter is drawing attention Fairfax Financial Holdings (TSX:FFH) just reported first quarter 2026 earnings, with net income of US$695.7 million versus US$945.7 million a year earlier, putting the stock in focus for many investors. See our latest analysis for Fairfax Financial Holdings. That earnings release and Fairfax’s plan to redeem CA$450 million of 4.70% senior notes land alongside a weaker 1-day share price return of 1.84% and a year to date share price return of...

Gulfport Energy (GPOR) opened 2026 with Q1 revenue of US$453.3 million and basic EPS of US$8.94, setting the tone for what the latest results say about margins and pricing across its portfolio. Over recent quarters, revenue has moved from US$338.1 million in Q1 2025 to US$350.1 million in Q4 2025 and now US$453.3 million in Q1 2026, while basic EPS has shifted from a small loss of US$0.07 in Q1 2025 to US$6.90 in Q4 2025 and US$8.94 in the latest quarter. With trailing twelve month EPS at...

Recent share performance and business snapshot NEXON (TSE:3659) has drawn attention after a one-month return of a 1.5% decline and a past three-month return of a 28.3% decline, prompting investors to reassess the stock alongside its latest financial profile. The company develops and distributes PC, mobile, and console games from its Tokyo base, with annual revenue of ¥475,102 and net income of ¥92,052. Revenue growth is 4.6% and net income growth is 10.4% on an annual basis, alongside a...

Marqeta (MQ) has just posted its Q1 2026 scorecard, reporting revenue of US$165.8 million and basic EPS of US$0.02, with the trailing twelve months showing total revenue of US$651.6 million and basic EPS of US$0.00. Over recent quarters, revenue has ranged from US$135.8 million in Q4 2024 to US$172.1 million in Q4 2025, while quarterly basic EPS has moved from a loss of US$0.05 in Q4 2024 to a profit of US$0.02 in Q1 2026. This sets up a results season in which the key question for investors...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

The ASX 200 is forecast to continue its positive momentum with a projected rise, reflecting optimism fueled by record highs on Wall Street and potential geopolitical resolutions. In this context, penny stocks remain an intriguing area of investment despite their historical connotations. These smaller or less-established companies can offer significant value when backed by strong financials, and we'll explore three such stocks that stand out for their potential in the Australian market.

CF Bankshares (CFBK) opened 2026 with Q1 total revenue of about US$14.2 million and basic EPS of roughly US$0.77, set against trailing 12 month revenue of about US$53.4 million and EPS of roughly US$2.79 that reflect 22.8% earnings growth over the past year. Over recent periods, the company has seen quarterly revenue move from about US$13.5 million in Q1 2025 to roughly US$14.2 million in Q1 2026, while basic EPS shifted from about US$0.68 to roughly US$0.77, supported by trailing net profit...

In the first quarter of 2026, Balchem Corporation reported higher sales of US$270.71 million and net income of US$40.29 million, alongside completing a share repurchase of 159,539 shares for US$25.85 million under its December 2025 buyback program. The combination of earnings growth and active capital returns signals management’s focus on both expanding the business and returning excess cash to shareholders. We’ll now examine how Balchem’s stronger earnings and completed buyback program...

Edgewell Personal Care (EPC) has put fresh numbers on the table for Q2 2026, reporting revenue of US$519.5 million and basic EPS of US$0.09. This comes against a backdrop of trailing 12 month revenue of US$2.2 billion and a basic EPS loss of US$0.23. Over the past few quarters the company has seen revenue move between US$415.1 million and US$627.2 million, while basic EPS has swung from a loss of US$0.66 to a profit of US$0.62. This performance sets the scene for investors to focus on how...

Sinclair (SBGI) has drawn fresh attention after recent price moves, with the stock up about 12% over the past month and roughly 8% in the past 3 months, compared with a modest 1-year total return. See our latest analysis for Sinclair. The recent 30 day share price return of 11.67% and 90 day share price return of 8.25% contrast with a modest 1.14% 1 year total shareholder return, which suggests that momentum has increased only in the shorter term. If Sinclair's moves have your attention, it...

Belden Inc. has reported past first-quarter 2026 results, with sales rising to US$696.38 million and GAAP diluted EPS from continuing operations at US$1.30, and has also issued second-quarter 2026 guidance for revenues of US$735 million to US$750 million and GAAP EPS of US$1.53 to US$1.63. Together with progress on its Joseph C. Belden Innovation Award finalists, these figures highlight how Belden is pairing earnings stability with initiatives that promote IT/OT convergence and data-driven...

California Resources (CRC) opened 2026 with Q1 revenue of US$967 million and a basic EPS loss of US$8.02 per share, setting a stark headline for the latest quarter. The company has seen quarterly revenue move between US$798 million and US$926 million over the last year, while EPS shifted from a profit of US$1.93 in Q2 2025 to smaller profits in subsequent quarters before this latest loss. This leaves investors weighing solid top line scale against pressure on margins. See our full analysis...

TransAlta’s Q1 2026 Earnings Snapshot TransAlta (TSX:TA) has opened 2026 with Q1 revenue of $565 million and basic EPS of $0.04, setting a more measured tone after a volatile run of recent quarters. The company has seen quarterly revenue move from $758 million and EPS of $0.15 in Q1 2025, through $433 million with an EPS loss of $0.38 in Q2 2025, to $565 million and a return to positive EPS in the latest period. Trailing 12 month net income remains a loss of $223 million on $2.2 billion of...